WO2013114416A1 - Lyophilized tablets of escitalopram oxalate for sublingual administration - Google Patents

Lyophilized tablets of escitalopram oxalate for sublingual administration Download PDF

Info

Publication number
WO2013114416A1
WO2013114416A1 PCT/IT2013/000028 IT2013000028W WO2013114416A1 WO 2013114416 A1 WO2013114416 A1 WO 2013114416A1 IT 2013000028 W IT2013000028 W IT 2013000028W WO 2013114416 A1 WO2013114416 A1 WO 2013114416A1
Authority
WO
WIPO (PCT)
Prior art keywords
amount
escitalopram oxalate
escitalopram
oxalate
mannitol
Prior art date
Application number
PCT/IT2013/000028
Other languages
French (fr)
Inventor
Leone Dall'asta
Original Assignee
Carthesia S.A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT000106A external-priority patent/ITMI20120106A1/en
Priority claimed from IT000105A external-priority patent/ITMI20120105A1/en
Application filed by Carthesia S.A.S. filed Critical Carthesia S.A.S.
Publication of WO2013114416A1 publication Critical patent/WO2013114416A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Definitions

  • the present invention relates to lyophilized tablets of escitalopram oxalate for sublingual administration, in particular, to a process for the preparation thereof, to the use of said lyophilized tablets for sublingual administration, or anyway by instantaneous dissolution in the mouth cavity, comprising escitalopram oxalate as an active ingredient thereof.
  • Escitalopram is the International Non-Proprietary Name of the (S)-1-[3-(dimethy
  • the (S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1 ,3-dihydro-5-isobenzofuran carbonitrile acid oxalate (1 :1 ), herein below referred to as escitalopram oxalate, is a selective serotonin reuptake inhibitor with central antidepressant activity.
  • This product is described in US Re. 34,712 and EP 347.066 as crystallized from acetone. Methods for its preparation, by chemical or chemo-enzymatic route, have been described, for example in US 7,834,201 , US 2007/0129561 and US 201 1/0238887.
  • Escitalopram oxalate is sparingly soluble in water and in ethanol. It is used in tablets and in drops. When in drops, escitalopram oxalate is dissolved in a water/96% ethanol mixture added with propyl gallate, citric acid, sodium hydroxide, containing escitalopram base in a concentration of 20 mg/ml.
  • WO 2009/150665 discloses an oro-dispersible pharmaceutical composition
  • escitalopram or salts thereof as active ingredient comprising excipients selected from the group consisting of cellulose derivatives, such as microcrystalline cellulose and the like, D-mannitol, lactose, dextrose, sorbitol, starch, xylitol, maltose, dicalcium phosphate and similar compounds; disintegrating agents and suitable pharmaceutical excipients.
  • WO 2009/135649 discloses a granulate comprising escitalopram oxalate having a particle size of less than 100 ⁇ and at least one filler, including preferably disintegrants or disintegration accelerators customary used in the pharmaceutical field.
  • IN 2006DE00964 discloses a solid dosage form of escitalopram, comprising escitalopram or pharmaceutically acceptable salts or solvates thereof, having a median particle size less than 20 ⁇ in admixture with one or more pharmaceutically acceptable excipients.
  • Said solid dosage form is prepared by a process comprising blending of said escitalopram and said excipients ensuring uniform distribution of escitalopram. Further said solid dosage form is preferably prepared by a direct compression technique.
  • IN 2007MU00470 discloses a pharmaceutical composition comprising escitalopram oxalate particles having a specific particle size distribution.
  • this document describes a tablet composition containing escitalopram oxalate, microcrystalline cellulose, croscarmellose sodium, colloidal silica, talc, and magnesium stearate in the core formulation.
  • US 2009/0048336 discloses the preparation of escitalopram oxalate powders having definite particle size distribution parameters.
  • the document describes processes for the preparation of escitalopram oxalate in powder comprising (1 ) the obtainment of a solution of escitalopram base in an organic solvent; (2) the reaction with oxalic acid to produce escitalopram oxalate and cause its precipitation as a solid; (3) the isolation of the solid; and (4) the micronization of the solid to obtain escitalopram oxalate with defined particle size parameters.
  • This document also discloses the preparation of compositions wherein the micronized particles are mixed with disintegrating agents.
  • US Re 34,712 and EP 347066 disclose the preparation of the (+) isomer of citalopram, i.e. of the (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1.3-dihydroisobenzofuran-5- carbonitrile (escitalopram base), and points out that its oxalate crystallized from acetone.
  • WO 2008/046617 discloses escitalopram or pharmaceutically acceptable salt and/or solvate thereof, including the oxalate, in the form of particles having a median particle size of less than 40 ⁇ and wherein the ratio between the median particle size and the particle size at the 95% quantile is equal to or greater than 0.42.
  • said escitalopram may be in amorphous or crystalline form, preferably it is in the form of crystalline particles used for direct compression and is included in pharmaceutical compositions which may comprise excipients.
  • WO 2006/123243 discloses the preparation of pharmaceutical dosage form comprising the steps (i) mixing escitalopram oxalate with one or more excipients, (ii) granulating the blend obtained in step (i) using solvent and optionally a binder, (iii) drying the granules obtained in step (ii), (iv) mixing the granules of step (iii) with one or more pharmaceutically acceptable excipients, (v) lubricating the mixture of step (iv) and (vi) compressing the blend of step (v) into tablets.
  • the excipients include disintegrating agents.
  • the literature does not disclose escitalopram oxalate lyophilized tablets obtainable from escitalopram oxalate aqueous solution wherein said escitalopram oxalate is dissolved at concentrations of at least 30 mg/ml and wherein common carriers are also dissolved.
  • escitalopram oxalate may be dissoved in water at a concentration of at least 30 mg/ml up to 1 15 mg/ml, advantageously from 50 mg/ml to 115 mg/ml, preferably from 60 mg/ml to 115 mg/ml.
  • escitalopram oxalate dissolves in water at the above concentrations in admixture with common pharmaceutical excipients or carriers.
  • escitalopram oxalate has been dissolved in water by mixing said escitalopram oxalate with two common carriers, D-mannitol and gelatin in appropriate proportions, in order to obtain clear aqueous solutions which are sufficiently stable to allow a subsequent freeze drying.
  • D-mannitol and gelatin escitalopram oxalate is present from 30% to 50% by weight, D-mannitol is from 45% to 75% by weight and gelatin is from 4% to 10% by weight.
  • said solution may contain ethanol and/or a salt selected from the group consisting of sodium chloride and magnesium chloride.
  • a salt selected from the group consisting of sodium chloride and magnesium chloride may also be contained in said solution.
  • the invention provides orosoluble, lyophilized tablets comprising escitalopram oxalate, D-mannitol, gelatin and, optionally, a salt selected from the group consisting of sodium chloride and magnesium chloride.
  • Said lyophilized tablets may also contain one or more adjuvants selected from the group consisting of preservative, flavoring and dying agents.
  • the invention also provides an escitalopram oxalate aqueous solution for pharmaceutical use comprising said escitalopram oxalate at a concentration of from 30 mg/ml to 115 mg/ml.
  • An aqueous solution containing escitalopram oxalate at so high concentrations allows the preparation of lyophilized compositions containing an effective amount of said escitalopram oxalate per unit form, in particular corresponding to 5 mg to 20 mg of base.
  • said solution contains escitalopram oxalate, D-mannitol and gelatin, escitalopram oxalate being dissolved at a concentration of at least 30 mg/ml, advantageously from 50 mg/ml to 1 15 mg/ml, preferably from 60 mg/ml to 1 15 mg/ml.
  • the present invention provides escitalopram oxalate lyophilized tablets for pharmaceutical use comprising escitalopram oxalate, D-mannitol, gelatin and, optionally, a salt selected from the group consisting of sodium chloride and magnesium chloride.
  • the present invention provides escitalopram oxalate lyophilized tablets comprising from 6 mg to 26 mg of escitalopram oxalate, from 24 mg to 41 mg of D- mannitol and from 2.17 mg to 5.6 mg of gelatin.
  • said lyophilized tablets comprise escitalopram oxalate, in an amount of 12.75 mg; D-mannitol, in an amount of from 27 mg to 41 mg; and gelatin, in an amount of from 3.8 mg to 5.6 mg.
  • escitalopram oxalate in an amount of 25.5 mg
  • D-mannitol in an amount of from 24 mg to 41 mg
  • gelatin in an amount of from 2.17 mg to 4.34 mg.
  • the present invention also provides a process for the preparation of the aforesaid escitalopram oxalate lyophilized tablets which comprises:
  • step (d) pouring a volume of the solution coming from step (c), containing a calculated amount of escitalopram oxalate, into the open cavity of a multi-cavity blister and submitting said blister to freeze drying.
  • the water used in step (a) may contain a salt selected from the group consisting of sodium chloride and magnesium chloride, dissolved therein at a concentration of from 0.9% to 1 %.
  • the content of escitalopram oxalate is from 30 mg/ml to 115 mg/ml.
  • a calculated amount of escitalopram oxalate is suspended in a volume of water, optionally containing 0.9%-1 % of sodium or magnesium chloride, sufficient for the desired concentration.
  • step (b) D-mannitol, in an amount of from 90% to 210% of said amount of said escitalopram oxalate, and gelatin, in an amount of from 10% to 45% of said amount of said escitalopram oxalate, are added to the suspension obtained at the end of step (a).
  • step (c) distilled water, optionally containing 0.9%-1 % sodium or magnesium chloride, or ethanol is added to the suspension of step (b) in order to obtain an escitalopram oxalate concentration of from 30 mg/ml to 115 mg/ml, preferably more than 30 mg/ml to 115 mg/ml and the temperature of the mixture is set at 20-30'C, preferably at 23-27'C, whereby a clear solution is obtained.
  • the suspension obtained at the end of step (b) is added with distilled water, or with a 0.9-1 % aqueous solution of a salt selected from the group consisting of sodium chloride or magnesium chloride, or with ethanol.
  • the solution may contain one or more adjuvants selected from the group consisting of preservative agents to improve the stability of the composition, flavoring and dying agents in view of the pharmaceutical use of the final product.
  • Preservatives such as methyl paraben, ethyl paraben, sodium benzoate, sorbic acid and its salts, in particular potassium sorbate, EDTA or salts thereof, may be present in a total amount of from 0.01 % to 0.3% w/v.
  • the flavoring agents are pharmaceutically acceptable flavors, tastes of synthetic and natural oils, the latter extracted from plants, leaves, flowers, fruits and their combinations, such as cinnamon, peppermint, anise and citron leaves, bitter almond, citrus fruits, in particular orange and/or lemon, linden and grapefruit oils.
  • chocolate, vanilla or eucalyptus flavor and essences of fruit, in particular apple, pear, peach, strawberry, cherry, apricot, orange, lemon and grapes may be advantageously used.
  • a flavoring agent may be generally present at a concentration of from 0.1 % to 0.25%.
  • Dyes may be present in an amount of 0.01%-0.02%.
  • the above adjuvants are added in step (b) or (c).
  • step (d) the solution obtained at the end of step (c) is freeze dried in order to directly obtain tablets for sublingual administration.
  • An escitalopram oxalate aqueous solution for pharmaceutical use comprising said escitalopram oxalate at a concentration of from 30 mg/ml to 1 15 mg/ml is a useful starting material for step (d).
  • An aqueous solution containing escitalopram oxalate at so high concentrations allows the preparation of pharmaceutical compositions containing an effective amount of said escitalopram oxalate, in particular an amount corresponding to 5 mg, 10 mg or 20 mg of escitalopram base per unit form.
  • said solution comprises escitalopram oxalate, D-mannitol and gelatin, said escitalopram oxalate being dissolved at a concentration of at least 25 mg/ml, advantageously from 30 mg/ml to 1 15 mg/ml, preferably from 35 mg/ml to 95 mg/ml.
  • escitalopram oxalate, D-mannitol and gelatin are present in the solution in an amount by weight in the ratios 1/from 0.9 to 2.2/from 0.04 to 0.1.
  • advantageous starting aqueous solutions comprise, as an active ingredient thereof, an effective amount by weight of escitalopram oxalate at a concentration of at least 25 mg/ml, advantageously from 30 mg/ml to 1 15 mg/ml, preferably from 35 mg/ml to 95 mg/ml, and further comprises D-mannitol, gelatin, in the above respective ratios, in respect of escitalopram oxalate and, optionally, ethanol, sodium chloride at a concentration of 0.9%-1 % or magnesium chloride at a concentration of 0.9%-1 %.
  • the amount of D-mannitol is from 90% to 210% the amount of escitalopram oxalate, while the amount of gelatin may vary from 10% to 45% of said amount of escitalopram oxalate.
  • the ingredients dissolved in the solution obtained at the end of step (c) are present in the following percentage: escitalopram oxalate, from 30% to 50% by weight; D- mannitol, from 45% to 70% by weight; and gelatin, from 4% to 10% by weight.
  • Advantageous aqueous solutions comprise, in percentage by weight, from 30% to 50% escitalopram oxalate, from 50% to 70% D-mannitol, and from 4% to 10% gelatin.
  • each cavity of the blister contains a lyophilized tablet comprising as an active ingredient thereof, an effective amount of escitalopram oxalate, said effective amount corresponding to 5 mg to 20 mg of escitalopram base, preferably being 12.75 mg or 25.5 mg, corresponding to 10 mg and 20 mg, respectively, of escitalopram base, in admixture with D-mannitol, gelatin and, optionally, sodium chloride or magnesium chloride. If one or more of the above-mentioned adjuvants were present in the solution obtained at the end of step (c), these adjuvants are also present in the lyophilized tablet.
  • Said adjuvant are selected from the group consisting of preservative, flavoring and dying agents.
  • the aliquots of the solution obtained at the end of step (c), which are introduced in each open cavity of a multi-cavity blister comprise a therapeutically effective amount of escitalopram oxalate, the calculated amounts of D-mannitol, and gelatin according to the above-mentioned ratios and, optionally, sodium chloride or magnesium chloride in the aforesaid percent range.
  • said aliquots of the used solution contain from 6 mg to 26 mg escitalopram oxalate; from 24 mg to 41 mg of D-mannitol; from 2.17 to 5.6 mg of gelatin, and, optionally, a salt selected from the group consisting of sodium chloride and magnesium chloride, in an amount of from 0.01 mg to 0.03 mg.
  • a lyophilized tablet comprising escitalopram oxalate, D-mannitol and gelatin in the above amount ranges is obtained.
  • escitalopram oxalate being in an amount of 12.75 mg, corresponding to 10 mg of escitalopram base, D- mannitol being in an amount of from 36 to 38 mg, up to 41 mg, and gelatin being in an amount of from 3.8 to 5.6 mg, at the end of the freeze drying lyophilized tablets comprising 12.75 mg of escitalopram oxalate are obtained.
  • Said lyophilized tablets which may contain one or more members selected from the group consisting of antioxidant, preservative and flavoring agents, are a preferred embodiment of the present invention.
  • step (c) by using, as advantageous solutions obtained at the end of step (c), those comprising, in percentage by weight, from 30% to 50%, from 45% to 70% and from 4% to 10% of escitalopram oxalate, D-mannitol and gelatin respectively, said escitalopram oxalate being in an amount of 25.5 mg, corresponding to 20 mg of escitalopram base, D-mannitol being in an amount of from 24 to 26 mg, up to 41 mg, and gelatin being in an amount of from 2.17 to 3.34 mg, up to 4.5, lyophilized tablets are obtained at the end of the freeze drying. These lyophilized tablets represent another preferred embodiment of the present invention.
  • the tablet of the present invention when put on or under the tongue, instantaneously dissolves and the escitalopram oxalate is absorbed without the presence of any disintegrating agent.
  • the present invention provides an aqueous solution for pharmaceutical use comprising an effective amount by weight of (S)-1-(4-fluorophenyl)-1 ,3-dihydro-5-isobenzo furancarbonitrile oxalate at a concentration of from 30 mg/ml to 115 mg/ml, advantageously of from 50 mg/ml to 115 mg/ml, preferably from 60 mg/ml to 115 mg/ml; D-mannitol in an amount by weight of from 90% to 210% the amount of escitalopram oxalate; and gelatin in an amount by weight of from 10% to 45% of the amount of escitalopram oxalate; and, optionally, ethanol in un amount by volume of 8-10% of the total volume of the solution.
  • the following examples illustrate the invention.
  • each cavity of the blister contained a tablet having the following composition:
  • Each lyophilized tablet contained an amount of escitalopram oxalate equivalent to 20.0 mg of escitalopram base.
  • each cavity of the blister contained a tablet having the following composition:
  • Each lyophilized tablet contained an amount of escitalopram oxalate equivalent to 10.0 mg of escitalopram base.
  • each cavity of the blister contained a tablet having the following composition:
  • Each lyophilized tablet contained an amount of escitalopram oxalate equivalent to
  • each cavity of the blister contained a tablet having the following composition:
  • Each lyophilized tablet contained an amount of escitalopram oxalate equivalent to 20.0 mg of escitalopram base.
  • each cavity of the blister contained a tablet having the following composition:
  • Each lyophilized tablet contained an amount of escitalopram oxalate equivalent to 20.0 mg of escitalopram base.
  • each cavity of the blister contained a tablet having the following composition:
  • Each lyophilized tablet contained an amount of escitalopram oxalate equivalent to 20.0 mg of escitalopram base.
  • each cavity of the blister contained a tablet having the following composition:
  • Each lyophilized tablet contained an amount of escitalopram oxalate equivalent to 20.0 mg of escitalopram base.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

There are described orosoluble, lyophilized tablets which instantaneously dissolve in the mouth, comprising escitalopram oxalate in admixture with D-mannitol and gelatin.

Description

LYOPHILIZED TABLETS OF ESCITALOPRAM OXALATE FOR SUBLINGUAL ADMINISTRATION
FIELD OF THE INVENTION
The present invention relates to lyophilized tablets of escitalopram oxalate for sublingual administration, in particular, to a process for the preparation thereof, to the use of said lyophilized tablets for sublingual administration, or anyway by instantaneous dissolution in the mouth cavity, comprising escitalopram oxalate as an active ingredient thereof.
BACKGROUND OF THE INVENTION
Escitalopram is the International Non-Proprietary Name of the (S)-1-[3-(dimethy| amino)propyl]-1-(4-fluorophenyl)-1 ,3-dihydro-5-isobenzofurancarbonitrile.
The (S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1 ,3-dihydro-5-isobenzofuran carbonitrile acid oxalate (1 :1 ), herein below referred to as escitalopram oxalate, is a selective serotonin reuptake inhibitor with central antidepressant activity. This product is described in US Re. 34,712 and EP 347.066 as crystallized from acetone. Methods for its preparation, by chemical or chemo-enzymatic route, have been described, for example in US 7,834,201 , US 2007/0129561 and US 201 1/0238887. Escitalopram oxalate is sparingly soluble in water and in ethanol. It is used in tablets and in drops. When in drops, escitalopram oxalate is dissolved in a water/96% ethanol mixture added with propyl gallate, citric acid, sodium hydroxide, containing escitalopram base in a concentration of 20 mg/ml.
PRIOR ART
In order to favorize the escitalopram oxalate absorption as well as possible, technologies involving micronization of particles and/or improvement in disintegration of the escitalopram oxalate granules and particles have been developed.
The above-mentioned US 7,834,201 (to Lundbeck & Co. A/S) document discloses oro-dispersible tablets having a hardness of at least 22 N (newtons) and an oro-dispersion time of less than 120 seconds, comprising an active pharmaceutical ingredient, escitalopram, adsorbed onto a water soluble filler, and one or more disintegrating agents.
Analogously, WO 2009/150665 (to Lupin Ltd.) discloses an oro-dispersible pharmaceutical composition comprising escitalopram or salts thereof as active ingredient; excipients selected from the group consisting of cellulose derivatives, such as microcrystalline cellulose and the like, D-mannitol, lactose, dextrose, sorbitol, starch, xylitol, maltose, dicalcium phosphate and similar compounds; disintegrating agents and suitable pharmaceutical excipients.
WO 2009/135649 (to Hexal AG) discloses a granulate comprising escitalopram oxalate having a particle size of less than 100 μηη and at least one filler, including preferably disintegrants or disintegration accelerators customary used in the pharmaceutical field. IN 2006DE00964 (to Jubilant Organosys Ltd.) discloses a solid dosage form of escitalopram, comprising escitalopram or pharmaceutically acceptable salts or solvates thereof, having a median particle size less than 20 μηι in admixture with one or more pharmaceutically acceptable excipients. Said solid dosage form is prepared by a process comprising blending of said escitalopram and said excipients ensuring uniform distribution of escitalopram. Further said solid dosage form is preferably prepared by a direct compression technique.
IN 2007MU00470 (to Torrent Pharm. Ltd) discloses a pharmaceutical composition comprising escitalopram oxalate particles having a specific particle size distribution. In particular this document describes a tablet composition containing escitalopram oxalate, microcrystalline cellulose, croscarmellose sodium, colloidal silica, talc, and magnesium stearate in the core formulation.
US 2009/0048336 (to Kolla et al., IN) discloses the preparation of escitalopram oxalate powders having definite particle size distribution parameters. In particular, the document describes processes for the preparation of escitalopram oxalate in powder comprising (1 ) the obtainment of a solution of escitalopram base in an organic solvent; (2) the reaction with oxalic acid to produce escitalopram oxalate and cause its precipitation as a solid; (3) the isolation of the solid; and (4) the micronization of the solid to obtain escitalopram oxalate with defined particle size parameters. This document also discloses the preparation of compositions wherein the micronized particles are mixed with disintegrating agents.
US Re 34,712 and EP 347066 disclose the preparation of the (+) isomer of citalopram, i.e. of the (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1.3-dihydroisobenzofuran-5- carbonitrile (escitalopram base), and points out that its oxalate crystallized from acetone.
WO 2008/046617 (to Ratiopharm Ltd.) discloses escitalopram or pharmaceutically acceptable salt and/or solvate thereof, including the oxalate, in the form of particles having a median particle size of less than 40 μητι and wherein the ratio between the median particle size and the particle size at the 95% quantile is equal to or greater than 0.42. According to this document, said escitalopram may be in amorphous or crystalline form, preferably it is in the form of crystalline particles used for direct compression and is included in pharmaceutical compositions which may comprise excipients.
WO 2006/123243 (to Aurobindo Ltd.) discloses the preparation of pharmaceutical dosage form comprising the steps (i) mixing escitalopram oxalate with one or more excipients, (ii) granulating the blend obtained in step (i) using solvent and optionally a binder, (iii) drying the granules obtained in step (ii), (iv) mixing the granules of step (iii) with one or more pharmaceutically acceptable excipients, (v) lubricating the mixture of step (iv) and (vi) compressing the blend of step (v) into tablets. The excipients include disintegrating agents.
The literature does not disclose escitalopram oxalate lyophilized tablets obtainable from escitalopram oxalate aqueous solution wherein said escitalopram oxalate is dissolved at concentrations of at least 30 mg/ml and wherein common carriers are also dissolved.
SUMMARY OF THE INVENTION
It has now been found a method which renders it possible to provide a new lyophilized tablet obtainable from a solution of escitalopram oxalate having a relatively high concentration. In particular, it has been found that escitalopram oxalate may be dissoved in water at a concentration of at least 30 mg/ml up to 1 15 mg/ml, advantageously from 50 mg/ml to 115 mg/ml, preferably from 60 mg/ml to 115 mg/ml.
It has also been found that escitalopram oxalate dissolves in water at the above concentrations in admixture with common pharmaceutical excipients or carriers. In particular, escitalopram oxalate has been dissolved in water by mixing said escitalopram oxalate with two common carriers, D-mannitol and gelatin in appropriate proportions, in order to obtain clear aqueous solutions which are sufficiently stable to allow a subsequent freeze drying. In the mixture of escitalopram oxalate, D-mannitol and gelatin, escitalopram oxalate is present from 30% to 50% by weight, D-mannitol is from 45% to 75% by weight and gelatin is from 4% to 10% by weight. No other agents are generally needed to dissolve escitalopram oxalate, even though a little amount of pure ethanol may be used. In addition, said solution may contain ethanol and/or a salt selected from the group consisting of sodium chloride and magnesium chloride. One or more adjuvants selected from the group consisting of preservative, antioxidant, flavoring and dying agents may also be contained in said solution.
The importance of disposing of an escitalopram oxalate solution wherein said escitalopram oxalate is present in relatively high concentrations is due to the fact that a freeze drying process requires even high substrate concentrations that, in the case of escitalopram oxalate, were heretofore unknown.
Thus, the invention provides orosoluble, lyophilized tablets comprising escitalopram oxalate, D-mannitol, gelatin and, optionally, a salt selected from the group consisting of sodium chloride and magnesium chloride. Said lyophilized tablets may also contain one or more adjuvants selected from the group consisting of preservative, flavoring and dying agents.
They may be used for sublingual administration in the treatment of the depression. The invention also provides an escitalopram oxalate aqueous solution for pharmaceutical use comprising said escitalopram oxalate at a concentration of from 30 mg/ml to 115 mg/ml. An aqueous solution containing escitalopram oxalate at so high concentrations allows the preparation of lyophilized compositions containing an effective amount of said escitalopram oxalate per unit form, in particular corresponding to 5 mg to 20 mg of base. More particularly, said solution contains escitalopram oxalate, D-mannitol and gelatin, escitalopram oxalate being dissolved at a concentration of at least 30 mg/ml, advantageously from 50 mg/ml to 1 15 mg/ml, preferably from 60 mg/ml to 1 15 mg/ml.
DETAILED DESCRIPTION
Thus, the present invention provides escitalopram oxalate lyophilized tablets for pharmaceutical use comprising escitalopram oxalate, D-mannitol, gelatin and, optionally, a salt selected from the group consisting of sodium chloride and magnesium chloride.
More particularly, the present invention provides escitalopram oxalate lyophilized tablets comprising from 6 mg to 26 mg of escitalopram oxalate, from 24 mg to 41 mg of D- mannitol and from 2.17 mg to 5.6 mg of gelatin.
Advantageously, said lyophilized tablets comprise escitalopram oxalate, in an amount of 12.75 mg; D-mannitol, in an amount of from 27 mg to 41 mg; and gelatin, in an amount of from 3.8 mg to 5.6 mg.
Other advantageous tablets comprise escitalopram oxalate, in an amount of 25.5 mg; D-mannitol, in an amount of from 24 mg to 41 mg; and gelatin, in an amount of from 2.17 mg to 4.34 mg.
The present invention also provides a process for the preparation of the aforesaid escitalopram oxalate lyophilized tablets which comprises:
(a) suspending an amount by weight of said escitalopram oxalate in a volume of water to obtain a suspension containing said escitalopram oxalate in an amount of from 30 mg/ml to 115 mg/ml;
(b) treating the suspension thus obtained with D-mannitol, in an amount by weight of from 90% to 210% the amount of said escitalopram oxalate; and gelatin, in an amount by weight of from 10% to 45% the amount of said escitalopram oxalate;
(c) adding the obtained mixture with water to obtain a suspension containing said escitalopram oxalate and heating the mixture at the temperature of from 20"C to 30"C until a clear solution is obtained; and
(d) pouring a volume of the solution coming from step (c), containing a calculated amount of escitalopram oxalate, into the open cavity of a multi-cavity blister and submitting said blister to freeze drying.
According to an embodiment, the water used in step (a) may contain a salt selected from the group consisting of sodium chloride and magnesium chloride, dissolved therein at a concentration of from 0.9% to 1 %. According to a preferred embodiment, in step (a) the content of escitalopram oxalate is from 30 mg/ml to 115 mg/ml. In practice, a calculated amount of escitalopram oxalate is suspended in a volume of water, optionally containing 0.9%-1 % of sodium or magnesium chloride, sufficient for the desired concentration.
In step (b), D-mannitol, in an amount of from 90% to 210% of said amount of said escitalopram oxalate, and gelatin, in an amount of from 10% to 45% of said amount of said escitalopram oxalate, are added to the suspension obtained at the end of step (a).
In step (c), distilled water, optionally containing 0.9%-1 % sodium or magnesium chloride, or ethanol is added to the suspension of step (b) in order to obtain an escitalopram oxalate concentration of from 30 mg/ml to 115 mg/ml, preferably more than 30 mg/ml to 115 mg/ml and the temperature of the mixture is set at 20-30'C, preferably at 23-27'C, whereby a clear solution is obtained. In practice, the suspension obtained at the end of step (b) is added with distilled water, or with a 0.9-1 % aqueous solution of a salt selected from the group consisting of sodium chloride or magnesium chloride, or with ethanol.
The solution may contain one or more adjuvants selected from the group consisting of preservative agents to improve the stability of the composition, flavoring and dying agents in view of the pharmaceutical use of the final product.
Preservatives, such as methyl paraben, ethyl paraben, sodium benzoate, sorbic acid and its salts, in particular potassium sorbate, EDTA or salts thereof, may be present in a total amount of from 0.01 % to 0.3% w/v.
The flavoring agents are pharmaceutically acceptable flavors, tastes of synthetic and natural oils, the latter extracted from plants, leaves, flowers, fruits and their combinations, such as cinnamon, peppermint, anise and citron leaves, bitter almond, citrus fruits, in particular orange and/or lemon, linden and grapefruit oils. Also chocolate, vanilla or eucalyptus flavor and essences of fruit, in particular apple, pear, peach, strawberry, cherry, apricot, orange, lemon and grapes may be advantageously used. A flavoring agent may be generally present at a concentration of from 0.1 % to 0.25%.
Dyes may be present in an amount of 0.01%-0.02%.
Preferably, the above adjuvants are added in step (b) or (c).
In step (d), the solution obtained at the end of step (c) is freeze dried in order to directly obtain tablets for sublingual administration.
An escitalopram oxalate aqueous solution for pharmaceutical use comprising said escitalopram oxalate at a concentration of from 30 mg/ml to 1 15 mg/ml is a useful starting material for step (d). An aqueous solution containing escitalopram oxalate at so high concentrations allows the preparation of pharmaceutical compositions containing an effective amount of said escitalopram oxalate, in particular an amount corresponding to 5 mg, 10 mg or 20 mg of escitalopram base per unit form.
Advantageously, said solution comprises escitalopram oxalate, D-mannitol and gelatin, said escitalopram oxalate being dissolved at a concentration of at least 25 mg/ml, advantageously from 30 mg/ml to 1 15 mg/ml, preferably from 35 mg/ml to 95 mg/ml.
According to this aspect of the invention, escitalopram oxalate, D-mannitol and gelatin are present in the solution in an amount by weight in the ratios 1/from 0.9 to 2.2/from 0.04 to 0.1.
More particularly, advantageous starting aqueous solutions comprise, as an active ingredient thereof, an effective amount by weight of escitalopram oxalate at a concentration of at least 25 mg/ml, advantageously from 30 mg/ml to 1 15 mg/ml, preferably from 35 mg/ml to 95 mg/ml, and further comprises D-mannitol, gelatin, in the above respective ratios, in respect of escitalopram oxalate and, optionally, ethanol, sodium chloride at a concentration of 0.9%-1 % or magnesium chloride at a concentration of 0.9%-1 %.
As mentioned above, the amount of D-mannitol is from 90% to 210% the amount of escitalopram oxalate, while the amount of gelatin may vary from 10% to 45% of said amount of escitalopram oxalate.
Thus, the ingredients dissolved in the solution obtained at the end of step (c) are present in the following percentage: escitalopram oxalate, from 30% to 50% by weight; D- mannitol, from 45% to 70% by weight; and gelatin, from 4% to 10% by weight. Advantageous aqueous solutions comprise, in percentage by weight, from 30% to 50% escitalopram oxalate, from 50% to 70% D-mannitol, and from 4% to 10% gelatin.
Aliquots of the solution obtained at the end of step (c), as illustrated above, containing a calculated amount of escitalopram oxalate, in particular the selected amount for the final lyophilized tablets, are introduced in the open cavity of a multi-cavity blister and said blister is submitted to freeze drying under conventional conditions.
At the end of the freeze drying, each cavity of the blister contains a lyophilized tablet comprising as an active ingredient thereof, an effective amount of escitalopram oxalate, said effective amount corresponding to 5 mg to 20 mg of escitalopram base, preferably being 12.75 mg or 25.5 mg, corresponding to 10 mg and 20 mg, respectively, of escitalopram base, in admixture with D-mannitol, gelatin and, optionally, sodium chloride or magnesium chloride. If one or more of the above-mentioned adjuvants were present in the solution obtained at the end of step (c), these adjuvants are also present in the lyophilized tablet.
Said adjuvant are selected from the group consisting of preservative, flavoring and dying agents.
According to an advantageous embodiment, the aliquots of the solution obtained at the end of step (c), which are introduced in each open cavity of a multi-cavity blister, comprise a therapeutically effective amount of escitalopram oxalate, the calculated amounts of D-mannitol, and gelatin according to the above-mentioned ratios and, optionally, sodium chloride or magnesium chloride in the aforesaid percent range. More particularly, said aliquots of the used solution contain from 6 mg to 26 mg escitalopram oxalate; from 24 mg to 41 mg of D-mannitol; from 2.17 to 5.6 mg of gelatin, and, optionally, a salt selected from the group consisting of sodium chloride and magnesium chloride, in an amount of from 0.01 mg to 0.03 mg. At the end of the freeze drying, a lyophilized tablet comprising escitalopram oxalate, D-mannitol and gelatin in the above amount ranges is obtained.
By using, as advantageous solutions obtained at the end of step (c), those comprising, in percentage by weight, from 20% to 50%, preferably from 30% to 50%, of escitalopram oxalate, from 45% to 70% of mannitol and from 4% to 10% of gelatin, said escitalopram oxalate being in an amount of 12.75 mg, corresponding to 10 mg of escitalopram base, D- mannitol being in an amount of from 36 to 38 mg, up to 41 mg, and gelatin being in an amount of from 3.8 to 5.6 mg, at the end of the freeze drying lyophilized tablets comprising 12.75 mg of escitalopram oxalate are obtained. Said lyophilized tablets, which may contain one or more members selected from the group consisting of antioxidant, preservative and flavoring agents, are a preferred embodiment of the present invention.
Similarly, by using, as advantageous solutions obtained at the end of step (c), those comprising, in percentage by weight, from 30% to 50%, from 45% to 70% and from 4% to 10% of escitalopram oxalate, D-mannitol and gelatin respectively, said escitalopram oxalate being in an amount of 25.5 mg, corresponding to 20 mg of escitalopram base, D-mannitol being in an amount of from 24 to 26 mg, up to 41 mg, and gelatin being in an amount of from 2.17 to 3.34 mg, up to 4.5, lyophilized tablets are obtained at the end of the freeze drying. These lyophilized tablets represent another preferred embodiment of the present invention.
The tablet of the present invention, when put on or under the tongue, instantaneously dissolves and the escitalopram oxalate is absorbed without the presence of any disintegrating agent.
Finally, the present invention provides an aqueous solution for pharmaceutical use comprising an effective amount by weight of (S)-1-(4-fluorophenyl)-1 ,3-dihydro-5-isobenzo furancarbonitrile oxalate at a concentration of from 30 mg/ml to 115 mg/ml, advantageously of from 50 mg/ml to 115 mg/ml, preferably from 60 mg/ml to 115 mg/ml; D-mannitol in an amount by weight of from 90% to 210% the amount of escitalopram oxalate; and gelatin in an amount by weight of from 10% to 45% of the amount of escitalopram oxalate; and, optionally, ethanol in un amount by volume of 8-10% of the total volume of the solution. The following examples illustrate the invention.
Example 1
(a) An amount of 2.55 g escitalopram oxalate was suspended in 20 ml of distilled water.
(b) The suspension thus obtained was added with 2.55 g of D-mannitol and 0.32 g of gelatin.
(c) The obtained suspension was added with distilled water to a weight of 38.4 g and a volume of 36.8 ml, then the temperature of the mixture was set at 25 , thus obtaining a clear solution, wherein the escitalopram oxalate concentration was of 69.30 mg/ml, having the following composition:
escitalopram oxalate 2'550 mg
D-mannitol 2'550 mg
gelatin 320 mg
distilled water to 36.8 ml
(d) From a volume of 5.15 ml of the solution obtained at the end of step (c), 0.368 ml of said solution was introduced in each cavity of a 14-cavity blister and said blister was submitted to freeze drying. At the end of the freeze drying, each cavity of the blister contained a tablet having the following composition:
escitalopram oxalate 25.5 mg
D-mannitol 25.5 mg
gelatin 3.2 mg
Total weight 54.2 mg
Each lyophilized tablet contained an amount of escitalopram oxalate equivalent to 20.0 mg of escitalopram base.
Example 2
(a) An amount of 1.275 g escitalopram oxalate was suspended in 20 ml of distilled water.
(b) The suspension thus obtained was added with 3.682 g of D-mannitol and 0.463 g of gelatin.
(c) The obtained suspension was added with distilled water to a weight of 38.4 g and a volume of 36.8 ml, then the temperature of the mixture was set at 25 , thus obtaining a clear solution, wherein the escitalopram oxalate concentration was of 34.65 mg/ml, having the following composition:
escitalopram oxalate 275 mg
D-mannitol 3'682 mg gelatin 463 mg
distilled water to 36.8 ml
(d) From a volume of 5.15 ml of the solution obtained at the end step (c), 0.368 ml of said solution was introduced in each cavity of a 14-cavity blister and said blister was submitted to freeze drying. At the end of the freeze drying, each cavity of the blister contained a tablet having the following composition:
escitalopram oxalate 12.75 mg
D-mannitol 36.82 mg
gelatin 4.63 mg
Total weight 54.20 mg
Each lyophilized tablet contained an amount of escitalopram oxalate equivalent to 10.0 mg of escitalopram base.
Example 3
(a) An amount of 4.00 g escitalopram oxalate, corresponding to 3.13 g escitalopram base, was suspended in 30 ml of a 0.9% aqueous solution of sodium chloride (escitalopram oxalate concentration: 133.333 mg/ml).
(b) The suspension thus obtained was added with 4 g of D-mannitol and 0.5 g of gelatin and subsequently a 0.9% aqueous solution of sodium chloride was added to a weight of 42.2 g.
(c) The obtained mixture was added with 4.5 ml of 96% pure ethanol and the temperature of the mixture was brought to 25 , thu s obtaining 44.8 ml of a clear solution, wherein the escitalopram oxalate concentration was of 89.686 mg/ml, having the following composition:
escitalopram oxalate 4Ό00 mg
D-mannitol 4Ό00 mg
gelatin 500 mg
Na+ 145 mg
cr 230 mg
96% ethanol 4.5 ml
distilled water to 44.8 ml
(d) From a volume of 3.99 ml of the solution obtained at the end step (c), 0.285 ml of said solution was introduced in each cavity of a 14-cavity blister and said blister was submitted to freeze drying. At the end of the freeze drying, each cavity of the blister contained a tablet having the following composition:
escitalopram oxalate 25.50 mg D-mannitol 25.50 mg
gelatin 3.18 mg
NaCI 0.02 mg
Total weight 54.20 mg
Each lyophilized tablet contained an amount of escitalopram oxalate equivalent to
20.0 mg of escitalopram base.
Example 4
(a) An amount of 2.55 g escitalopram oxalate was suspended in 20 ml of a 1 % aqueous solution of magnesium chloride (escitalopram oxalate concentration: 127.5 mg/ml).
(b) The suspension thus obtained was added with 3.8 g of D-mannitol, 0.48 g of gelatin. The suspension was added with a 1% aqueous solution of magnesium chloride to a volume of 27.2 ml.
(c) The obtained suspension was added with 4.5 ml of 96% pure ethanol and the temperature of the mixture was brought to 25Ό, thu s obtaining a clear solution, wherein the escitalopram oxalate concentration was of 80.442 mg/ml, having the following composition: escitalopram oxalate 2'550 mg
D-mannitol 3'800 mg
gelatin 480 mg
Mg++ 64 mg
CI" 185 mg
ethanol 96% 4.5 ml
distilled water to 31.6 ml
(d) From a volume of 4.42 ml of the solution obtained at the end step (c), 0.357 ml of said solution was introduced in each cavity of a 14-cavity blister and said blister was submitted to freeze drying. At the end of the freeze drying, each cavity of the blister contained a tablet having the following composition:
escitalopram oxalate 25.50 mg
D-mannitol 38.00 mg
gelatin 4.80 mg
MgCI2 0.02 mg
Total weight 68.32 mg
Each lyophilized tablet contained an amount of escitalopram oxalate equivalent to 20.0 mg of escitalopram base.
Example 5
(a) An amount of 2.55 g escitalopram oxalate was suspended in 20 ml of a 1 % aqueous solution of magnesium chloride (escitalopram oxalate concentration: 127.5 mg/ml).
(b) The obtained suspension thus obtained was added with 3.8 g of D-mannitol and 0.48 g of gelatin and subsequently with a 1 % aqueous solution of magnesium chloride to a weight of 29.8 g.
(c) The temperature of the mixture was brought to 25 , thus obtaining a clear solution, wherein the escitalopram oxalate concentration was of 80.315 mg/ml, having the following composition:
escitalopram oxalate 2'550 mg
D-mannitol 3'800 mg
gelatin 480 mg
Mg" 64 mg
cr 185 mg
distilled water to 31.75 ml
(d) From 4.44 ml of the solution obtained at the end step (c), 0.317 ml of said solution was introduced in each cavity of a 14-cavity blister and said blister was submitted to freeze drying. At the end of the freeze drying, each cavity of the blister contained a tablet having the following composition:
escitalopram oxalate 25.50 mg
D-mannitol 38.00 mg
Gelatin 4.80 mg
MgCI2 0.02 mg
Total weight 68.32 mg
Each lyophilized tablet contained an amount of escitalopram oxalate equivalent to 20.0 mg of escitalopram base.
Example 6
(a) An amount of 2.55 g escitalopram oxalate was suspended in 20 ml of a 1 % aqueous solution of magnesium chloride (escitalopram oxalate concentration: 127.5 mg/ml).
(b) The obtained suspension was added with 2.55 g of D-mannitol, 0.32 g of gelatin and 0.001 g of black cherry flavour and subsequently with a 1 % aqueous solution of magnesium chloride to a volume of 31.92 ml.
(c) The temperature of the mixture was brought to 25'C, thus obtaining a clear solution, wherein the escitalopram oxalate concentration was of 79.887 mg/ml, having the following composition:
escitalopram oxalate 2'550 mg
D-mannitol 2'550 mg gelatin 320 mg
Mg++ 64 mg
CI' 185 mg
black cherry flavour 1 mg
distilled water to 31.92 ml
(d) From 4.47 ml of the solution obtained at the end step (c), 0.319 ml of said solution was introduced in each cavity of a 14-cavity blister and said blister was submitted to freeze drying. At the end of the freeze drying, each cavity of the blister contained a tablet having the following composition:
escitalopram oxalate 25.50 mg
D-mannitol 25.50 mg
gelatin 3.20 mg
MgCI2 0.02 mg
black cherry flavour 0.01 mg
Total weight 54.23 mg
Each lyophilized tablet contained an amount of escitalopram oxalate equivalent to 20.0 mg of escitalopram base.
Example 7
(a) An amount of 2.55 g escitalopram oxalate was suspended in 20 ml of a 1 % aqueous solution of magnesium chloride (escitalopram oxalate concentration: 127.5 mg/ml).
(b) The obtained suspension thus obtained was added with 2.55 g of D-mannitol, 0.32 g of gelatin and subsequently with a 1 % aqueous solution of magnesium chloride to a volume of 31.92 ml.
(c) The temperature of the mixture was brought to 25"C, thus obtaining a clear solution, wherein the escitalopram oxalate concentration was of 79.887 mg/ml, having the following composition:
escitalopram oxalate 2'550 mg
D-mannitol 2'550 mg
gelatin 320 mg
Mg++ 64 mg
CI' 185 mg
distilled water to 31.92 ml
(d) From 4.47 ml of the solution obtained at the end step (c), 0.319 ml of said solution was introduced in each cavity of a 14-cavity blister and said blister was submitted to freeze drying. At the end of the freeze drying, each cavity of the blister contained a tablet having the following composition:
escitalopram oxalate 25.50 mg
D-mannitol 25.50 mg
gelatin 3.20 mg
MgCI2 0.02 mg
Total weight 54.22 mg
Each lyophilized tablet contained an amount of escitalopram oxalate equivalent to 20.0 mg of escitalopram base.

Claims

1. Lyophilized tablets of escitalopram oxalate for sublingual administration, comprising an effective amount of (S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1 ,3-dihydro-5- isobenzofurancarbonitrile oxalate (escitalopram oxalate), D-mannitol, in an amount by weight of from 90% to 210% the amount of escitalopram oxalate; and gelatin, in an amount by weight of from 10% to 45% the amount of escitalopram oxalate.
2. Tablets of claim 1 wherein the contents by weight of escitalopram oxalate, D- mannitol, and gelatin is from 30% to 50%, from 45% to 70% and from 4% to 10%, respectively.
3. Tablets of any one of claims 1 and 2, also comprising a salt selected from the group consisting of sodium chloride and magnesium chloride, in an amount of from 0.02% to 0.04%.
4. Tablets according to any one of claims from 1 to 3, also comprising one or more members selected from the group consisting of preservative, antioxidant, flavoring and dying agents.
5. Tablets according to any one of claims 1 to 4 wherein escitalopram oxalate is in an amount of from 6 mg to 26 mg, D-mannitol is an amount of from 24 mg to 41 mg, and gelatin is in an amount of from 2.17 mg to 5.6 mg.
6. Tablets according to any one of claims 1 to 5, wherein said effective amount of escitalopram oxalate is equivalent to 5 mg, 10 mg or 20 mg of escitalopram base.
7. Tablets according to claim 5, wherein escitalopram oxalate is in an amount of 12.75 mg; D-mannitol is in an amount of from 27 mg to 41 mg; and gelatin is in an amount of from
3.8 mg to 5.6 mg.
8. Tablets according to claim 5, wherein escitalopram oxalate is in an amount of 25.5 mg; D-mannitol is in an amount of from 24 mg to 41 mg; and gelatin is in an amount of from 2.17 mg to 4.34 mg.
9. Tablets according to any one of claims 7 and 8, also containing a salt selected from the group consisting of sodium chloride and magnesium chloride, in an amount of from 0.01 mg to 0.03 mg.
10. A process for the preparation of lyophilized tablets of escitalopram oxalate, which comprises
(a) suspending an amount by weight of said escitalopram oxalate in a volume of water to obtain a suspension containing said escitalopram oxalate in an amount of from 40 mg/ml to 150 mg/ml;
(b) treating the suspension thus obtained with D-mannitol, in an amount by weight of from 90% to 210% the amount of said escitalopram oxalate; and gelatin, in an amount by weight of from 10% to 45% the amount of said escitalopram oxalate;
(c) adjusting the volume of the obtained suspension with water or ethanol to obtain a suspension containing said escitalopram oxalate in an amount of from 30 mg/ml to 1 15 mg/ml and heating the mixture at the temperature of from 20 to 3013 until a clear solution is obtained; and
(d) pouring a volume of the solution coming from step (c), containing a calculated amount of escitalopram oxalate, into the open cavity of a multi-cavity blister and submitting said blister to freeze drying.
1 1 . The process of claim 10 wherein, in step (a), the used water contains a salt selected from the group consisting of sodium chloride and magnesium chloride at a concentration of from 0.9% to 1 %.
12. The process of claim 1 1 , wherein one or more adjuvants selected from the group consisting of preservative, antioxidant, flavoring and dying agents are added in step (b) or (c).
13. An aqueous solution for pharmaceutical use comprising an amount by weight of (S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1 ,3-dihydro-5-isobenzofurancarbonitrile oxalate at a concentration of from 30 mg/ml to 1 15 mg/ml, D-mannitol in an amount by weight of from 90% to 210% the amount of escitalopram oxalate, and gelatin in an amount by weight of from 10% to 45% the amount of escitalopram oxalate; and, optionally, ethanol in an amount by volume of 8-10% the total volume of the solution.
PCT/IT2013/000028 2012-01-30 2013-01-30 Lyophilized tablets of escitalopram oxalate for sublingual administration WO2013114416A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
ITMI2012A000106 2012-01-30
ITMI2012A000105 2012-01-30
IT000106A ITMI20120106A1 (en) 2012-01-30 2012-01-30 LIOFILIZED PADS OF ESCITALOPRAM OXALATE FOR SUBLINGUAL ADMINISTRATION
IT000105A ITMI20120105A1 (en) 2012-01-30 2012-01-30 AQUEOUS SOLUTION OF OXALED ESCITALOPRAM AND ITS USE
ITMI2012A000448 2012-03-22
IT000448A ITMI20120448A1 (en) 2012-01-30 2012-03-22 LIOFILIZED COMPOSITION OF ESCITALOPRAM OXALATE FOR SUBLINGUAL ADMINISTRATION

Publications (1)

Publication Number Publication Date
WO2013114416A1 true WO2013114416A1 (en) 2013-08-08

Family

ID=46832825

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2013/000028 WO2013114416A1 (en) 2012-01-30 2013-01-30 Lyophilized tablets of escitalopram oxalate for sublingual administration

Country Status (2)

Country Link
IT (1) ITMI20120448A1 (en)
WO (1) WO2013114416A1 (en)

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0347066A1 (en) 1988-06-14 1989-12-20 H. Lundbeck A/S New enantiomers and their isolation
WO2003011278A1 (en) * 2001-07-31 2003-02-13 H. Lundbeck A/S Crystalline composition containing escitalopram
WO2006106531A1 (en) * 2005-04-04 2006-10-12 Jubilant Organosys Ltd Process for the preparation of escitalopram or its acid addition salts
WO2006123243A2 (en) 2005-05-20 2006-11-23 Aurobindo Pharma Limited Pharmaceutical dosage forms comprising escitalopram in form of granules
US20070129561A1 (en) 2002-08-12 2007-06-07 Naoki Taoka Method for the separation of intermediates which may be used for the preparation of escitalopram
WO2008046617A1 (en) 2006-10-20 2008-04-24 Ratiopharm Gmbh Escitalopram and solid pharmaceutical composition comprising the same
US20090048336A1 (en) 2007-08-17 2009-02-19 Naveen Kumar Kolla Escitalopram oxalate powders
WO2009135649A1 (en) 2008-05-07 2009-11-12 Hexal Ag Granulate comprising escitalopram oxalate
WO2009150665A1 (en) 2008-06-09 2009-12-17 Lupin Limited Orally disintegrating pharmaceutical compositions of escitalopram and salts thereof
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
WO2010149196A1 (en) * 2008-10-23 2010-12-29 Genepharm A.E. Taste masked dosage form of pharmaceutically acceptable salt of escitalopram
US20110238887A1 (en) 2010-03-24 2011-09-29 Apple Inc. Hybrid-device storage based on environmental state

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100999510A (en) * 2006-01-13 2007-07-18 美德（江西）生物科技有限公司 Preparation of noncrystal form ede plene oxalate and its coprecipitate
EP2359812A1 (en) * 2010-01-18 2011-08-24 Cephalon France Oral lyophilised compositions

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE34712E (en) 1988-06-14 1994-08-30 H. Lundbeck A/S Pharmaceutically useful (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroiso benzofuran-5-carbonitrile and non-toxic acid addition salts thereof
EP0347066A1 (en) 1988-06-14 1989-12-20 H. Lundbeck A/S New enantiomers and their isolation
WO2003011278A1 (en) * 2001-07-31 2003-02-13 H. Lundbeck A/S Crystalline composition containing escitalopram
US20070129561A1 (en) 2002-08-12 2007-06-07 Naoki Taoka Method for the separation of intermediates which may be used for the preparation of escitalopram
WO2006106531A1 (en) * 2005-04-04 2006-10-12 Jubilant Organosys Ltd Process for the preparation of escitalopram or its acid addition salts
WO2006123243A2 (en) 2005-05-20 2006-11-23 Aurobindo Pharma Limited Pharmaceutical dosage forms comprising escitalopram in form of granules
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
WO2008046617A1 (en) 2006-10-20 2008-04-24 Ratiopharm Gmbh Escitalopram and solid pharmaceutical composition comprising the same
US20090048336A1 (en) 2007-08-17 2009-02-19 Naveen Kumar Kolla Escitalopram oxalate powders
WO2009135649A1 (en) 2008-05-07 2009-11-12 Hexal Ag Granulate comprising escitalopram oxalate
WO2009150665A1 (en) 2008-06-09 2009-12-17 Lupin Limited Orally disintegrating pharmaceutical compositions of escitalopram and salts thereof
WO2010149196A1 (en) * 2008-10-23 2010-12-29 Genepharm A.E. Taste masked dosage form of pharmaceutically acceptable salt of escitalopram
US20110238887A1 (en) 2010-03-24 2011-09-29 Apple Inc. Hybrid-device storage based on environmental state

Also Published As

Publication number Publication date
ITMI20120448A1 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
EP0557065B1 (en) Spheroid formulation
EP2005945B1 (en) Oseltamivir phosphate granule and preparation method thereof
US20070196472A1 (en) Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
US6534527B2 (en) Edible herbal compositions for relieving nicotine craving
JP2005501074A (en) Paroxetine / glycyrrhizinate
US11957791B2 (en) Methods
AU2019331490A1 (en) Novel methods
WO2006053089A3 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
DE102016014603A1 (en) Synthetic ayahuasca
GB2595140A (en) Flupentixol/melitracen pharmaceutical composition and preparation thereof
US20080125453A1 (en) Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions
US20040013752A1 (en) Buccal and sublingual mucosally absorbed herbal compositions for relieving nicotine withdrawal symptoms and craving for nicotine and nicotine containing substances
EP0205865B1 (en) Pharmaceutical preparations with an antihypertensive and cardioprotective effect
CA2719608A1 (en) Orodispersable formulations of phosphodiesterase-5 (pde-5) inhibitors
WO2013114416A1 (en) Lyophilized tablets of escitalopram oxalate for sublingual administration
JP2002527385A (en) Sertraline oral concentrate
JPH1171269A (en) Oral liquid pharmaceutical preparation
ITMI20120105A1 (en) AQUEOUS SOLUTION OF OXALED ESCITALOPRAM AND ITS USE
ITMI20120106A1 (en) LIOFILIZED PADS OF ESCITALOPRAM OXALATE FOR SUBLINGUAL ADMINISTRATION
JPS6045162B2 (en) antidepressants
JP2001064159A (en) Composite granular preparation
HU204997B (en) Process for producing carrier system suitable for ensuring controlled biological access to dihydropyridines, as well as new oral dosage form ensuring improved biological access
JP2885668B2 (en) Teprenone formulation
MXPA03002013A (en) Tablets containing epinastine manufactured by direct compression.
KR101611349B1 (en) Pharmaceutical preparation with improved stability comprising silymarin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13710070

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13710070

Country of ref document: EP

Kind code of ref document: A1